Anbio Biotechnology (NNNN) Liabilities and Shareholders Equity (2023 - 2025)

Anbio Biotechnology (NNNN) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $30.2 million in Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity rose 59.83% year-over-year to $30.2 million in Q4 2025; TTM through Dec 2025 was $27680.7 billion, a N/A change from a year earlier, with the FY2025 full-year figure at $30.2 million, up 59.83% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $30.2 million, down from $27680.6 billion in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for NNNN reached as high as $27680.6 billion in Q2 2025 and fell as low as $15.8 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $6920.2 billion across 3 years, with a median of $24.6 million in 2024.
• Across the five-year window, Liabilities and Shareholders Equity rose 19.67% in 2024 and soared 59.83% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $15.8 million in 2023, then climbed by 19.67% to $18.9 million in 2024, then surged by 59.83% to $30.2 million in 2025.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $30.2 million in Q4 2025, $27680.6 billion in Q2 2025, and $18.9 million in Q4 2024.